Andere Sprachen Vistagen Therapeutics, Inc.

Aktien

A3EHA1

US92840H4002

VTGN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.06.2024			% 5 Tage	% 1. Jan.
3,23 ^USD	-3,58 %		-5,56 %	-37,16 %

11.06.	Transcript : Vistagen Therapeutics, Inc., Q4 2024 Earnings Call, Jun 11, 2024
11.06.	Vistagen Therapeutics, Inc. meldet Ergebnis für das am 31. März 2024 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Vistagen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	11.06.
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update	11.06.
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024	07.06.
Vistagen to Present at the Jefferies Global Healthcare Conference	29.05.
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology Conference	24.05.
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference	23.05.
Vistagen Therapeutics, Inc. to Present At the 2024 American Society of Clinical Psychopharmacology Conference	23.05.
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference	07.05.
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	25.04.
Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	25.04.
Vistagen to Present at the 2024 Anxiety and Depression Association Conference	10.04.
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference	09.04.
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	01.04.
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	01.04.
Vistagen to Present at Stifel 2024 Virtual CNS Days	11.03.
Vistagen to Present at TD Cowen 44th Annual Health Care Conference	28.02.
Vistagen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13.02.
Earnings Flash (VTGN) VISTAGEN Posts Q3 Revenue $411,400	13.02.
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update	13.02.
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vistagen Therapeutics, Inc.

Aktien

A3EHA1

US92840H4002

VTGN

Andere Sprachen

Filter